Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azithromycin in an experimental Staphylococcus aureus abscess model

D M Bamberger1, B L Herndon, P R Suvarna

  • 1Section of Infectious Diseases, University of Missouri-Kansas City School of Medicine 64108-2792, USA.

The Journal of Antimicrobial Chemotherapy
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spectrum of disease caused by Rhodococcus equi in human immunodeficiency virus infection: Report of a case and review of the literature.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Multiple growth factors regulate coronary embryonic vasculogenesis.

Developmental dynamics : an official publication of the American Association of Anatomists·2001
Same author

Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Successful treatment of multiple cerebral histoplasmomas with itraconazole.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same author

Diagnosis and treatment of osteomyelitis.

Comprehensive therapy·2000
Same author

A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.

The New England journal of medicine·2000
Same journal

β-lactam susceptibility testing of ampicillin-susceptible non-faecalis enterococcal clinical isolates in France.

The Journal of antimicrobial chemotherapy·2026
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Azithromycin effectively reduced Staphylococcus aureus bacterial concentrations in rabbit abscess models. This antibiotic achieved significant bacterial reduction and culture-negativity in infected tissue cages.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Staphylococcus aureus abscesses pose significant treatment challenges.
  • Understanding antibiotic efficacy in localized infections is crucial.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetics of azithromycin.
  • To assess azithromycin's effectiveness in a rabbit Staphylococcus aureus abscess model.

Main Methods:

  • Rabbits received 15 mg/kg/day azithromycin in infected (24h or 2-week old) and uninfected tissue cages.
  • Azithromycin concentrations were measured in tissue cage fluid.
  • Bacterial concentrations were quantified after 8 days of therapy.

Main Results:

Related Experiment Videos

  • Azithromycin concentrations were higher in infected compared to uninfected tissue cages.
  • A significant reduction of approximately 3 log10 cfu/mL in bacterial concentrations was observed in treated groups.
  • 50% of 24h and 29% of 2-week infected cages became culture-negative.

    • Conclusions:

    • Azithromycin demonstrates significant efficacy in reducing bacterial burden in a Staphylococcus aureus abscess model.
    • The drug's pharmacokinetic profile supports its effectiveness in infected tissues.
    • Azithromycin offers a potential therapeutic option for S. aureus abscesses.